{"id":59727,"date":"2026-03-17T16:28:55","date_gmt":"2026-03-17T08:28:55","guid":{"rendered":"https:\/\/flcube.com\/?p=59727"},"modified":"2026-03-17T16:28:56","modified_gmt":"2026-03-17T08:28:56","slug":"alphamab-oncology-doses-first-patient-in-jskn027-phase-i-trial-first-in-class-pd-l1-vegfr2-bispecific-adc-enters-clinic","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=59727","title":{"rendered":"Alphamab Oncology Doses First Patient in JSKN027 Phase I Trial \u2013 First\u2011in\u2011Class PD\u2011L1\/VEGFR2 Bispecific ADC Enters Clinic"},"content":{"rendered":"\n<p><strong>Alphamab Oncology<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/9966:HKG\">HKG: 9966<\/a>) has successfully dosed the <strong>first patient<\/strong> in the <strong>Phase I clinical study<\/strong> of <strong>JSKN027<\/strong>, a <strong>first\u2011in\u2011class PD\u2011L1\/VEGFR2 bispecific antibody\u2011drug conjugate (ADC)<\/strong>, marking entry into human trials for the dual\u2011target oncology candidate targeting advanced malignant solid tumors.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-milestone\">Clinical Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Study Number<\/strong><\/td><td>JSKN027-101<\/td><\/tr><tr><td><strong>Phase<\/strong><\/td><td>Phase I (open\u2011label, multi\u2011center)<\/td><\/tr><tr><td><strong>Design<\/strong><\/td><td>Dose\u2011escalation + dose\u2011expansion<\/td><\/tr><tr><td><strong>First Patient Dosed<\/strong><\/td><td>16\u202fMar\u202f2026<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Advanced malignant solid tumors (basket trial design)<\/td><\/tr><tr><td><strong>Primary Endpoints<\/strong><\/td><td>Safety, tolerability, PK\/PD, preliminary anti\u2011tumor activity<\/td><\/tr><tr><td><strong>Dose\u2011Finding Goal<\/strong><\/td><td>Maximum tolerated dose (MTD) and\/or recommended Phase II dose (RP2D)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> <strong>JSKN027<\/strong> \u2013 independently developed by Alphamab Oncology<\/li>\n\n\n\n<li><strong>Class:<\/strong> <strong>Bispecific ADC<\/strong> (antibody\u2011drug conjugate)<\/li>\n\n\n\n<li><strong>Dual Targets:<\/strong><\/li>\n\n\n\n<li><strong>PD\u2011L1<\/strong> (programmed death ligand 1) \u2013 immune checkpoint inhibition<\/li>\n\n\n\n<li><strong>VEGFR2<\/strong> (vascular endothelial growth factor receptor 2) \u2013 anti\u2011angiogenic signaling<\/li>\n\n\n\n<li><strong>Innovation Status:<\/strong> <strong>First\u2011in\u2011class<\/strong> potential \u2013 no approved bispecific ADC combining PD\u2011L1 and VEGFR2 targeting in global development<\/li>\n\n\n\n<li><strong>Therapeutic Hypothesis:<\/strong> Simultaneous blockade of immune evasion (PD\u2011L1) and tumor vascularization (VEGFR2) may generate synergistic anti\u2011tumor effects beyond monospecific ADC or checkpoint inhibitor monotherapy<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-strategy-amp-competitive-context\">Development Strategy &amp; Competitive Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Dimension<\/th><th>JSKN027 Position<\/th><th>Market Implication<\/th><\/tr><\/thead><tbody><tr><td><strong>Mechanism Differentiation<\/strong><\/td><td>Dual\u2011target bispecific ADC vs. single\u2011target ADCs (Enhertu, Trodelvy) and PD\u20111\/PD\u2011L1 inhibitors<\/td><td>Potential to address resistance mechanisms in checkpoint inhibitor\u2011refractory populations<\/td><\/tr><tr><td><strong>Pipeline Stage<\/strong><\/td><td>Phase I entry (first\u2011in\u2011human)<\/td><td>3\u20114 years to potential approval assuming successful development<\/td><\/tr><tr><td><strong>Alphamab ADC Platform<\/strong><\/td><td>Built on proprietary bispecific and conjugation technologies<\/td><td>Validates platform beyond existing HER2\u2011targeted assets (JSKN003, JSKN033)<\/td><\/tr><tr><td><strong>Solid Tumor Scope<\/strong><\/td><td>Basket trial design (multiple tumor types)<\/td><td>Enables rapid efficacy signal detection across indications<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-outlook\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Bispecific ADC Market Trajectory:<\/strong> Global bispecific ADC pipeline remains nascent (&lt;20 clinical\u2011stage assets); JSKN027&#8217;s dual\u2011checkpoint\/angiogenesis mechanism represents novel biology in a field dominated by HER2 and TROP2\u2011targeted monospecific ADCs.<\/li>\n\n\n\n<li><strong>Alphamab Portfolio Synergies:<\/strong> JSKN027 joins JSKN003 (HER2\u2011targeted ADC, Phase III) and JSKN033 (PD\u2011L1\/HER2 bispecific ADC, Phase II) in Alphamab&#8217;s ADC franchise, diversifying target coverage and reducing single\u2011asset risk.<\/li>\n\n\n\n<li><strong>Combination Potential:<\/strong> PD\u2011L1\/VEGFR2 bispecific architecture positions JSKN027 for future combination studies with chemotherapy, radiotherapy, or additional immunotherapy agents \u2013 a flexibility constrained in approved single\u2011mechanism ADCs.<\/li>\n\n\n\n<li><strong>Investor Catalyst Timeline:<\/strong> Phase I dose\u2011escalation data expected H2 2026\u2011H1 2027; initial efficacy signals in dose\u2011expansion cohorts likely 2027\u20112028, contingent on MTD\/RP2D establishment.<\/li>\n\n\n\n<li><strong>Regulatory Pathway Considerations:<\/strong> First\u2011in\u2011class status may qualify for breakthrough therapy designation in major markets upon demonstration of superior efficacy in defined tumor populations; China NMPA innovation pathway applicable given domestic development and unmet need positioning.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical development timelines, efficacy expectations, and regulatory pathways for JSKN027. Actual results may differ materially due to risks including safety findings, dose\u2011limiting toxicities, competitive dynamics, and regulatory requirements.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026031601709_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026031601709_c.\"><\/object><a id=\"wp-block-file--media-27f9ebe2-cb7a-4c4d-a0f9-6b242b7c095a\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026031601709_c.pdf\">2026031601709_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026031601709_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-27f9ebe2-cb7a-4c4d-a0f9-6b242b7c095a\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Alphamab Oncology (HKG: 9966) has successfully dosed the first patient in the Phase I clinical&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[35,187,62,854],"class_list":["post-59727","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-adc-xdc","tag-alphamab-oncology","tag-clinical-trial-approval-initiation","tag-hkg-9966"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Alphamab Oncology Doses First Patient in JSKN027 Phase I Trial \u2013 First\u2011in\u2011Class PD\u2011L1\/VEGFR2 Bispecific ADC Enters Clinic - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Alphamab Oncology (HKG: 9966) has successfully dosed the first patient in the Phase I clinical study of JSKN027, a first\u2011in\u2011class PD\u2011L1\/VEGFR2 bispecific antibody\u2011drug conjugate (ADC), marking entry into human trials for the dual\u2011target oncology candidate targeting advanced malignant solid tumors.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=59727\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alphamab Oncology Doses First Patient in JSKN027 Phase I Trial \u2013 First\u2011in\u2011Class PD\u2011L1\/VEGFR2 Bispecific ADC Enters Clinic\" \/>\n<meta property=\"og:description\" content=\"Alphamab Oncology (HKG: 9966) has successfully dosed the first patient in the Phase I clinical study of JSKN027, a first\u2011in\u2011class PD\u2011L1\/VEGFR2 bispecific antibody\u2011drug conjugate (ADC), marking entry into human trials for the dual\u2011target oncology candidate targeting advanced malignant solid tumors.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=59727\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-17T08:28:55+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-17T08:28:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59727#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59727\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Alphamab Oncology Doses First Patient in JSKN027 Phase I Trial \u2013 First\u2011in\u2011Class PD\u2011L1\\\/VEGFR2 Bispecific ADC Enters Clinic\",\"datePublished\":\"2026-03-17T08:28:55+00:00\",\"dateModified\":\"2026-03-17T08:28:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59727\"},\"wordCount\":498,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ADC \\\/ XDC\",\"Alphamab Oncology\",\"Clinical trial approval \\\/ initiation\",\"HKG: 9966\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59727#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59727\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=59727\",\"name\":\"Alphamab Oncology Doses First Patient in JSKN027 Phase I Trial \u2013 First\u2011in\u2011Class PD\u2011L1\\\/VEGFR2 Bispecific ADC Enters Clinic - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-03-17T08:28:55+00:00\",\"dateModified\":\"2026-03-17T08:28:56+00:00\",\"description\":\"Alphamab Oncology (HKG: 9966) has successfully dosed the first patient in the Phase I clinical study of JSKN027, a first\u2011in\u2011class PD\u2011L1\\\/VEGFR2 bispecific antibody\u2011drug conjugate (ADC), marking entry into human trials for the dual\u2011target oncology candidate targeting advanced malignant solid tumors.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59727#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59727\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59727#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Alphamab Oncology Doses First Patient in JSKN027 Phase I Trial \u2013 First\u2011in\u2011Class PD\u2011L1\\\/VEGFR2 Bispecific ADC Enters Clinic\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Alphamab Oncology Doses First Patient in JSKN027 Phase I Trial \u2013 First\u2011in\u2011Class PD\u2011L1\/VEGFR2 Bispecific ADC Enters Clinic - Insight, China&#039;s Pharmaceutical Industry","description":"Alphamab Oncology (HKG: 9966) has successfully dosed the first patient in the Phase I clinical study of JSKN027, a first\u2011in\u2011class PD\u2011L1\/VEGFR2 bispecific antibody\u2011drug conjugate (ADC), marking entry into human trials for the dual\u2011target oncology candidate targeting advanced malignant solid tumors.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=59727","og_locale":"en_US","og_type":"article","og_title":"Alphamab Oncology Doses First Patient in JSKN027 Phase I Trial \u2013 First\u2011in\u2011Class PD\u2011L1\/VEGFR2 Bispecific ADC Enters Clinic","og_description":"Alphamab Oncology (HKG: 9966) has successfully dosed the first patient in the Phase I clinical study of JSKN027, a first\u2011in\u2011class PD\u2011L1\/VEGFR2 bispecific antibody\u2011drug conjugate (ADC), marking entry into human trials for the dual\u2011target oncology candidate targeting advanced malignant solid tumors.","og_url":"https:\/\/flcube.com\/?p=59727","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-17T08:28:55+00:00","article_modified_time":"2026-03-17T08:28:56+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=59727#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=59727"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Alphamab Oncology Doses First Patient in JSKN027 Phase I Trial \u2013 First\u2011in\u2011Class PD\u2011L1\/VEGFR2 Bispecific ADC Enters Clinic","datePublished":"2026-03-17T08:28:55+00:00","dateModified":"2026-03-17T08:28:56+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=59727"},"wordCount":498,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ADC \/ XDC","Alphamab Oncology","Clinical trial approval \/ initiation","HKG: 9966"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=59727#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=59727","url":"https:\/\/flcube.com\/?p=59727","name":"Alphamab Oncology Doses First Patient in JSKN027 Phase I Trial \u2013 First\u2011in\u2011Class PD\u2011L1\/VEGFR2 Bispecific ADC Enters Clinic - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-03-17T08:28:55+00:00","dateModified":"2026-03-17T08:28:56+00:00","description":"Alphamab Oncology (HKG: 9966) has successfully dosed the first patient in the Phase I clinical study of JSKN027, a first\u2011in\u2011class PD\u2011L1\/VEGFR2 bispecific antibody\u2011drug conjugate (ADC), marking entry into human trials for the dual\u2011target oncology candidate targeting advanced malignant solid tumors.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=59727#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=59727"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=59727#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Alphamab Oncology Doses First Patient in JSKN027 Phase I Trial \u2013 First\u2011in\u2011Class PD\u2011L1\/VEGFR2 Bispecific ADC Enters Clinic"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59727","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=59727"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59727\/revisions"}],"predecessor-version":[{"id":59729,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59727\/revisions\/59729"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=59727"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=59727"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=59727"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}